2022
DOI: 10.1016/j.gim.2022.02.006
|View full text |Cite
|
Sign up to set email alerts
|

Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
6

Relationship

3
3

Authors

Journals

citations
Cited by 8 publications
(8 citation statements)
references
References 37 publications
0
8
0
Order By: Relevance
“… Additional findings included 77 noncancer, medically actionable secondary finding genes (Amendola et al, 2022). …”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“… Additional findings included 77 noncancer, medically actionable secondary finding genes (Amendola et al, 2022). …”
Section: Resultsmentioning
confidence: 99%
“…The measures for health literacy, housing insecurity, and food insecurity are explained and cited in the CHARM protocol paper (Mittendorf et al, 2021). c Additional findings included 77 noncancer, medically actionable secondary finding genes (Amendola et al, 2022).…”
Section: Incorrect Interpretationmentioning
confidence: 99%
“…Participants received exome‐based panel testing through a CLIA‐certified laboratory at the University of Washington 15 . Variants were annotated in 39 genes associated with hereditary cancer risk and 77 noncancer, medically actionable secondary finding genes 16 . Genetic testing results were classified as either pathogenic/likely pathogenic (P/LP) variant(s); negative (benign and likely benign variants); or only variants of uncertain significance (VUS).…”
Section: Methodsmentioning
confidence: 99%
“…The Cancer Health Assessment Reaching Many (CHARM) study developed and tested a multimodal intervention designed to increase access to clinically indicated genetic testing and to narrow inequities in cancer genetic service delivery 15 . Specifically, CHARM piloted a hereditary cancer risk assessment program in Kaiser Permanente Northwest (KPNW), an integrated health care delivery system in Oregon and southwest Washington state, and Denver Health (DH), an integrated safety‐net health system in Denver County, Colorado 16 . Patient recruitment prioritized outreach to groups with historically limited access to cancer genetic testing, including low income, low literacy, and minoritized racial and ethnic groups, as well as individuals with limited or unknown family history.…”
Section: Introductionmentioning
confidence: 99%
“…Recruitment efforts were enriched for medically underserved populations at both sites based on previously defined methods [ 31 ]. The study defined enrolled participants with one or more of the following barriers to healthcare access as belonging to medically underserved populations: (1) Hispanic ethnicity or a race other than White; (2) residing in a Health Resources and Services Administration–defined medically underserved census tract; (3) Spanish language preference for the risk assessment or any subsequent study survey; (4) educational attainment less than high school graduate; (5) income < 200% of the Federal Poverty Level; (6) use of Medicaid insurance or being uninsured; (7) sexual orientation other than heterosexual; (8) gender identity other than cisgender female/male [ 34 ]. The KPNW Institutional Review Board (IRB) approved this study and all collaborating IRBs ceded to KPNW or approved the study separately.…”
Section: Methodsmentioning
confidence: 99%